If you told me five years ago that cancer care would be cracked open, not by biotech, not by billion-dollar pharma, but by a personalized coaching platform built on lifestyle medicine, I would’ve laughed and ordered another bourbon. But here we are in 2025, and Complement 1 just dropped a $16M seed round with the precision of a heavyweight jab.
Let’s talk players: Owl Ventures and Blume Ventures led the round, with a crew of healthcare focused angels riding shotgun. They’re not just betting on health tech, they’re betting on a new operating system for cancer care, one built from the ground up by people who know how to scale. CEO Karan Bajaj, the mind behind WhiteHat Jr, and COO Trupti Mukker, who took the reins after him, aren’t rookies. They’ve danced with unicorns, exited big, and now they’re back, with a bigger purpose and better tech.
Complement 1 is headquartered in NYC, but they’re playing a national game. Their platform isn’t your typical once-a-week Zoom check-in with a health coach who forgot your name. This is daily 1:1 guidance tailored by AI, powered by humans, and rooted in the gritty details of each patient’s cancer type, treatment stage, and real-time symptoms. Think somatic practices, customized movement, trauma-informed care, backed by hard science and an IRB approved clinical trial. No crystals. No guesswork.
Over 90% adherence rate. Thirty-seven percent fewer side effects. Eighteen percent less pain. Twenty-seven percent better sleep. Not opinions. Outcomes. Meanwhile, actuarial models forecast a 30% cut in cancer-related healthcare costs. This isn’t wellness washed wishful thinking, it’s a strategic strike at the $200B+ cancer care economy.
And the tech? A rule engine crafted alongside the American Institute for Cancer Research, paired with real-time data from wearables and self-reports. The engine adapts, learns, and refines. It doesn’t just respond, it anticipates. Complement 1 isn’t just tracking metrics. It’s training behavior, building resilience, and anchoring a new model of survivorship.
With folks like Dr. Neil Iyengar from Memorial Sloan Kettering Cancer Center on the board and deep partnerships with health systems, they’re not circling the industry, they’re integrating into its bloodstream. And their targets? Cancer patients, survivors, and the millions of high-risk Americans no one’s been talking to until now.
Complement 1 is proof that sometimes the most powerful medicine isn’t found in a bottle, but in the daily choices we’re coached to make, one meal, one breath, one moment at a time.
Let’s connect and keep the momentum going across the tech ecosystem. Whether you’re a founder shaping the future, a leader driving change, a VC backing bold ideas, or an investor spotting the next big thing—together, we’re pushing boundaries. Proud to be building the future with you.
Let’s connect on LinkedIn and Twitter (X), and keep the conversation going.
Thank you, Vention. Without your support, none of this would be possible.